Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Adding dexmedetomidine to spinal bupivacaine for pain relief during knee surgery

Official title: The Analgesic Effect of Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery: A Randomized Double-Blinded Dose-Finding Trial

Run by Cairo University · NCT07522736 · Data updated 2026-11-12

This trial tests whether small intrathecal doses of dexmedetomidine added to spinal bupivacaine can prolong pain relief after knee surgery in adult men.

More Liposomal Bupivacaine trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment120 (estimated)
SponsorCairo University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedMarch 1, 2025
Main results expectedAugust 30, 2026
Study endsAugust 30, 2026
Registry record updatedApril 13, 2026
Trial IDNCT07522736 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are male adults aged 18–65 with ASA I–II scheduled for knee orthopedic surgery who have no contraindications to regional anesthesia.

Probably not a fit

Patients who are female, outside the 18–65 age range, have contraindications to regional anesthesia, a history of hypersensitivity to the drugs, psychiatric disorders, or recent opioid/CNS depressant use are unlikely to qualify or benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares three intrathecal doses of dexmedetomidine (4, 8, and 12 μg) given with hyperbaric bupivacaine for patients undergoing knee orthopedic surgery. The primary outcome is duration of analgesia and the secondary outcome is the profile of adverse effects. Male adults aged 18–65 with ASA physical status I–II are eligible and receive a single spinal anesthetic with the assigned adjunct dose. The study is conducted at a single center (Cairo University) and monitors postoperative pain duration and safety measures without increasing the local anesthetic dose.

Why it matters

Potential benefit: If successful, adding intrathecal dexmedetomidine could provide longer-lasting spinal anesthesia and reduce the need for postoperative opioids.

How similar studies have gone: Previous clinical reports have shown that dexmedetomidine as an intrathecal adjunct can enhance and prolong analgesia, though optimal dosing strategies remain under study.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age from 18 to 65 years.
* American Society of Anesthesiologists (ASA) physical status I-II.
* Male patients scheduled for knee orthopedic surgery.

Exclusion Criteria:

* Patients with psychiatric disorders.
* History of drug addiction.
* Contraindication for regional anesthesia.
* History of hypersensitivity to the study drugs.
* Previous administration of opioids and/or other central nervous system depressants during current hospital admission.

Where it's running

  • Cairo University
    Cairo, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.